The oral testosterone effectively increased testosterone levels and reduced SHBG, showing promise for treating testosterone deficiency.
April 2026 in “The Journal of Urology” Finasteride and dutasteride reduce semen quality, with dutasteride having a stronger negative effect.
75 citations
,
October 1996 in “Dermatologic Clinics” Chronic Telogen Effluvium is a hair loss condition in middle-aged women that usually doesn't lead to complete baldness.
4 citations
,
March 2002 in “International journal of toxicology” LAAM caused developmental toxicity in tolerant rats without causing birth defects.
7 citations
,
April 2012 in “Clinical investigation” Transdermal testosterone can improve sexual desire in postmenopausal women but lacks long-term safety data and is not FDA-approved for this use.
April 2024 in “Dermatovenerologiâ, kosmetologiâ” Telogen effluvium is a common hair loss condition that can be managed with proper treatment and addressing underlying issues.
110 citations
,
October 2019 in “Translational Andrology and Urology” More men are getting benign prostatic hyperplasia, and there are many treatments, from medication to surgery, with new methods being developed.
April 2023 in “Journal of Investigative Dermatology” Increased TEMRA cells can predict treatment outcomes in rapidly progressive alopecia areata.
2 citations
,
March 2021 in “Dermatologic Therapy” Low-level laser therapy helps increase hair growth in female pattern hair loss but not in telogen effluvium.
7 citations
,
January 2003 in “Journal of cosmetic and laser therapy” The filterless flashlamp-based system effectively delays hair regrowth and improves skin condition.
5 citations
,
January 2023 in “Fertility and sterility” Doctors are preparing to potentially perform uterus transplants in transgender women, considering technical, hormonal, and ethical factors.
May 2026 in “International Journal of Drug Delivery Technology” Adrenaline infiltration improves hair transplant efficiency and safety.
18 citations
,
August 2019 in “Clinical breast cancer” Local hormonal treatment for vulvovaginal atrophy is likely safe for women with estrogen receptor-positive breast cancer on aromatase inhibitors.
January 2025 in “Dermatologic Therapy” The laser treatment improved hair appearance and was safe and well-received by patients.
3 citations
,
March 2013 in “International Journal of Clinical Practice” Combination therapy for 9+ months maintains symptom improvements after stopping alpha-blockers or finasteride.
2 citations
,
March 2021 in “Clinical Cosmetic and Investigational Dermatology” Tracking invalid extraction rates can improve hair transplant outcomes by assessing surgeon skill.
June 2024 in “Archives of dermatological research” Targeted testing for telogen effluvium patients can save healthcare costs.
54 citations
,
October 2019 in “Cochrane library” Some drugs may reduce prostatitis symptoms short-term with few side effects.
10 citations
,
January 2017 in “Skin appendage disorders” Emotional stress can trigger intermittent hair loss in chronic telogen effluvium, which may not improve with treatment if stress continues.
2 citations
,
February 2020 in “Journal of Investigative Surgery” Flutamide-induced hypospadias in rats slows down early wound healing.
January 2019 in “Chulalongkorn Medical Journal” Using a special laser and platelet-rich plasma together is safe and improves hair growth in men with hair loss.
1 citations
,
September 2024 in “African Journal of Urology” Dutasteride is slightly better than finasteride for treating BPH but has fewer sexual side effects.
25 citations
,
August 2022 in “Frontiers in Reproductive Health” Platelet-rich plasma shows promise for treating erectile dysfunction, but more research is needed.
September 2022 in “Journal of The American Academy of Dermatology” Combining dutasteride mesotherapy with oral minoxidil is more effective for hair loss than using oral minoxidil alone.
January 2013 in “CINECA IRIS Institutial research information system (University of Pisa)” December 2022 in “Journal of The European Academy of Dermatology and Venereology” The 7.1% withdrawal rate was in the oral finasteride group, not the topical one.
November 2022 in “Journal of the Endocrine Society” A woman's masculine symptoms were caused by a rare tumor in her left ovary, which was found using a special blood test.
May 2025 in “The Journal of Dermatology”
April 2023 in “Journal of Investigative Dermatology” An automated system can predict death risk in thin melanoma by analyzing immune cells.
October 2006 in “Urology” The study found that different criteria led to different patient groups in the CombAT study compared to the MTOPS study.